Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN3Z5D
|
|||
| Drug Name |
L-DOS47
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1], [2] | |
| Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 1/2 | [3] | ||
| Company |
Helix BioPharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02340208) A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of Helix BioPharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.